Orphan designation: surovatamig Treatment of B-lymphoblastic leukaemia/lymphoma, 21/11/2025 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 27 March 2026 - 15:17

Orphan designation: surovatamig Treatment of B-lymphoblastic leukaemia/lymphoma, 21/11/2025 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3150

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters